| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3990882 | Journal of Thoracic Oncology | 2009 | 5 Pages |
Introduction:Little information is available concerning the prognosis and treatment of metastasis-induced acute pancreatitis (MIAP) with lung cancer. The aim of this study was to investigate the prognostic factors of MIAP patients with lung cancer.Methods:A retrospective study of 20 MIAP patients with lung cancer was performed. Survival was estimated using Kaplan-Meier method. Prognostic factors were assessed with Cox proportional hazards regression model.Results:There were 14 men and six women; 15 cases were non-small cell lung cancer and five cases were small cell lung cancer. The median age was 68 (range, 41–83). The mean duration from lung cancer to MIAP diagnosis of having MIAP was 139.8 days (range, 3–892). However, two small cell lung cancer cases had preceded presentation with acute pancreatitis. Chemotherapy (p = 0.008; hazards ratio = 4.99; 95% confidence interval = 1.51–16.54) and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) (p = 0.007; hazards ratio = 6.13; 95% confidence interval = 0.04–0.61) were significant prognostic factors for survival. ECOG PS 3 to 4 at diagnosis of MIAP was 11/20. Survival of MIAP with lung cancer was 108.7 days. Patients with ECOG PS 3 to 4 had shorter mean survival than those with PS 0 to 2 (33.7 versus 226.4 days; p = 0.003). Chemotherapy group had longer mean survival than those without chemotherapy (161.9 versus 25.0 days; p = 0.01).Conclusion:Chemotherapy can improve survival of MIAP from bronchogenic carcinoma in the selected patients.
